Cabaletta Bio, Inc.

Cabaletta Bio, Inc. is a clinical-stage biotechnology company dedicated to developing innovative engineered T cell therapies for patients suffering from severe autoimmune diseases. The company's core strategy revolves around designing and advancing novel cell-based treatments that target the underlying causes of these debilitating conditions. Cabaletta Bio's lead product candidate, resecabtagene autoleucel, is a sophisticated fully human CD19-CAR T therapy currently undergoing Phase 1/2 clinical trials. This therapy is being investigated for a range of challenging autoimmune indications including dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris, systemic sclerosis, and generalized myasthenia gravis. Beyond its lead program, Cabaletta Bio is also advancing DSG3-CAART, a chimeric antigen receptor T (CAAR T) cell therapy in Phase 1 trials for mucosal pemphigus vulgaris, and MuSK-CAART, another investigational cell therapy in Phase 1 trials for anti-muscle-specific kinase (MuSK) antibody-positive myasthenia gravis. The company leverages strategic collaborations with leading academic institutions and specialized contract development and manufacturing organizations to accelerate its research and development pipeline, positioning itself at the forefront of cell therapy innovation for autoimmune disorders.